LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Ticker SymbolLIVN
Company nameLivaNova PLC
IPO dateOct 19, 2015
CEOMr. Vladimir A. Makatsaria
Number of employees2900
Security typeOrdinary Share
Fiscal year-endOct 19
Address20 Eastbourne Terrace
CityLONDON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeW2 6LG
Phone442033250662
Websitehttps://www.livanova.com/
Ticker SymbolLIVN
IPO dateOct 19, 2015
CEOMr. Vladimir A. Makatsaria
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data